About us

CSR

Corporate Social Responsibility

Ability Pharmaceuticals is an innovative and responsible company regarding the relationship with our stakeholders, suppliers, partners, institutions, employees, the environment and society. The objective of our Corporate Social Responsibility is to achieve a sustainable development of the company, understood as a balanced growth in the economic, social and environmental dimensions. At Ability Pharmaceuticals we integrate all of our stakeholders with the commitment to develop cancer medications to improve clinical outcomes through improved efficacy and increased safety.
 
Knowledge sharing and co-development are highly valued at Ability Pharmaceuticals. We work with an extensive network of excellent external partners, from the public and private sectors, with the aim of creating new projects and generating new business opportunities. Ability Pharmaceuticals breaks traditional boundaries between partner companies and promotes the integration of resources and ideas among development groups, organizations and different business units.
 
Ability Pharmaceuticals promotes ethical behavior that builds trust and brings value. That is why the company maintains a responsible, fluid and bidirectional communication with the main interest groups, about the policies, practices and results of our projects. In addition, Ability Pharmaceuticals is committed to respect the ethical codes, carrying out all our activities with professional, ethical and total transparency.
 
We believe that our employees are critical to our social commitment and we are aware that attracting, training and working with tomorrow's leaders and innovators is vital to helping us achieve our business philosophy. That is why Ability Pharmaceuticals supports the training and professional development of all its employees, facilitating family reconciliation and work, as part of the retention strategy of the extraordinary professionals who form the company. Moreover, the company is committed to equal opportunity for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, language or disability.
 
We have a great commitment to the environment, considering fundamental the protection of the field in which our business is developed, since only this way can maintain a sustainable and lasting activity. We promote a healthy and safe work atmosphere for our employees, continually improving to protect the health, safety and welfare of workers.

LATEST NEWS

18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
20.02.2017

News

Ability Pharmaceuticals launches a new updated website with a fresh design + info
15.12.2016

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
22.11.2016

News

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients + info
11.05.2016

News

Ability Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. + info
07.04.2015

News

Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma. + info
14.02.2014

News

Ability Pharmaceuticals to Present at the 7th Annual European Life Sciences CEO Forum in Zurich, March 4-5, 2014. + info
05.02.2014

News

ABILITY PHARMACEUTICALS Initiates Clinical Trial with its Dual mTORC1/C2 Inhibitor ABTL0812 in Patients with Lung and Pancreatic Cancer + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
Credits